Switching from Liraglutide to Tirzepatide: What the Evidence Actually Shows

The biggest misconception: that switching is just a dose swap

Many people approaching this transition assume it works like switching between two similar antihypertensives — same class, rough equivalence, adjust the milligrams. That's not how it works here, and getting this wrong matters.

Liraglutide (Saxenda) activates a single receptor pathway: the GLP-1 receptor. Tirzepatide (Mounjaro) activates two (GLP-1 and GIP) which is why it sits in a different pharmacological class altogether, the dual agonists. The mechanisms overlap but aren't identical, which means the side-effect profile, the titration schedule, and the clinical expectations are all distinct. There is no published washout-then-restart protocol that applies universally; your prescriber will make a judgement based on your current dose, how long you've been on liraglutide, and how your body has responded.

The practical implication: tirzepatide's starting dose of 2.5mg exists to let your system adjust, it is not a therapeutic weight-loss dose. If you arrive expecting to pick up where Saxenda left off, the first few weeks may feel slower than anticipated. That's by design. A prescriber who understands your background can frame those early weeks correctly so you don't abandon a switch that's working exactly as it should.

For a broader look at how moving between GLP-1 and dual-agonist medicines is approached clinically, our guide to switching from GLP-1 medicines to tirzepatide covers the category-level picture. If you are already on Mounjaro and considering a move to a newer agent, our page on switching from Mounjaro to retatrutide explains how that step-up transition is approached clinically.

What the trial data shows, and what it doesn't prove about your switch

The numbers between these two medicines are not close. In the SURMOUNT-1 trial (2,539 adults with obesity and no diabetes, 72 weeks), tirzepatide produced an average body-weight reduction of around 20–21% at the 15mg maintenance dose (with some analyses reaching approximately 22.5%) as published in the New England Journal of Medicine. Liraglutide 3mg, in comparable populations over a similar duration, produced average reductions in the region of 5–8%, based on the SCALE trial programme.

Below is a factual side-by-side of the two medicines as licensed in the UK.

*Trial figures cited from the NEJM SURMOUNT-1 publication and NICE technology appraisal TA1026. Individual results vary; clinical trial populations differ from general practice.

The trial data makes tirzepatide look like a clear upgrade. What it cannot show is how your body specifically will respond after a period on liraglutide, or whether any comorbidity you're managing changes the risk-benefit calculation. The evidence informs the decision; it doesn't replace it. For a head-to-head breakdown focused specifically on the efficacy question, this page examines whether liraglutide outperforms tirzepatide in clinical context.

Side effects: overlapping but not identical

Both medicines share a GI-led side-effect profile. Nausea, loose stools, constipation, indigestion and reduced appetite are common to both, particularly at the start of treatment or after a dose step. For most people these settle within the first couple of weeks of a new dose. If you've managed liraglutide's GI effects without difficulty, you may find tirzepatide's profile broadly familiar, though that's not guaranteed, and the dual mechanism does produce a somewhat different pattern of gastric slowing.

One practical checking habit worth building when you start any new GLP-1 or dual-agonist medicine: look at the injection site briefly after each dose, redness, swelling or firmness that doesn't resolve within a few days is worth mentioning to your prescriber. It takes under a minute and catches local reactions early.

The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but serious risk across the GLP-1 class. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention, don't wait to contact your prescriber if that happens. You can report any suspected side effect at the MHRA's Yellow Card scheme.

Pregnancy, breastfeeding and actively trying to conceive are contraindications for both medicines. Tirzepatide carries an additional note: women on oral contraceptives should use a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because gut-slowing effects may reduce pill absorption. For oral contraceptives, semaglutide does not carry the same evidence of reduced absorption.

What IS available through nume, and how the clinical decision gets made

nume does not dispense liraglutide (Saxenda) for weight loss. The licensed UK weight-management medicines we prescribe are tirzepatide (Mounjaro) and semaglutide (Wegovy). If you're currently on Saxenda and want to explore a move to tirzepatide, that conversation starts with a clinical assessment, not a product page.

The weight-loss treatments consultation page is the starting point. A GPhC-registered prescriber reviews your case the same day, your current treatment, your dose history, any conditions relevant to the switch, and your eligibility under the licensed criteria (BMI ≥30, or ≥27 with a weight-related comorbidity such as high blood pressure, type 2 diabetes or obstructive sleep apnoea). NHS England's guidance on weight-management injections sets out the clinical framework that informs those assessments.

Which medicine suits you is a clinical decision our prescribers make with you, based on your history, your goals and your health. If you want to understand how the two medicines differ before that conversation, our tirzepatide versus liraglutide page walks through the key differences in mechanism, dosing and outcomes. Cost is sometimes part of the picture too, our Mounjaro price comparison guide sets out what private treatment typically costs in the UK and what a legitimate price should include. You can also read more about who we are and our clinical approach before you start.